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Congenital heart defects (CHD) are the commonest congenital malformations and remain a major
cause of neonatal mortality and morbidity in the developed world [1,2]. Critical congenital heart
defects (CCHD) are the most serious form of CHD, with an incidence of between two and three per
1000 live births [3]. Babies with CCHD are at risk of cardiovascular collapse, acidosis, and death in
the first few days of life, usually following closure of the ductus arteriosus; therefore, early diagnosis
is essential to reduce the possibility of these complications and also to improve outcomes following
cardiac surgery [1,2].
In high-income countries, most babies are routinely screened for CCHD using antenatal
ultrasound scanning and postnatal physical examination. However, both of these procedures have a
relatively low detection rate, and up to a third of babies with CCHD may be discharged from hospital
before a diagnosis is made [4,5].
Pulse oximetry (PO) measures blood oxygen saturations and is a well-established, accurate,
non-invasive method of detecting low oxygen levels (hypoxaemia) [1,2]. The rationale for using PO
to screen for CCHD is that hypoxaemia is present in the majority of cases of CCHD, but the degree
of desaturation is often comparatively mild and may be clinically undetectable, even by experienced
clinicians [6]. Therefore, the addition of PO screening (POS) following delivery will detect those babies
with hypoxaemia, who can then be assessed and the presence of a CCHD established before the babies
develop acute collapse [1].
Proof of concept and feasibility of POS was first established by a number of small single centre
studies in the early 2000s, but the low prevalence of CCHD in these studies meant that there was
insufficient evidence to precisely define the test accuracy, and firm recommendations for routine
screening could not be made [2,7]. Between 2008 and 2012, several large European studies provided
sufficient, robust evidence of test accuracy which could reliably inform the possible introduction of
routine POS [8–12].
In 2012, a systematic review and meta-analysis of all available evidence (including nearly
230,000 screened babies) concluded that pulse oximetry screening was a moderately sensitive,
highly specific test for detection of CCHD, which met the criteria for universal screening [13]. In 2014,
the world’s largest POS study involving over 120,000 babies from China [14] demonstrated similar findings
which essentially removed any remaining uncertainties about the performance of PO screening [15].
The addition of POS reduces the ‘diagnostic gap’ for CCHD [10] (i.e. those babies who are
not detected by existing screening methods), and when POS is combined with antenatal ultrasound
scanning and the newborn physical examination, between 92% and 96% of babies with CCHD are
identified in a timely manner [16].
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Attitudes towards POS are changing, and acceptance of the potential benefits is becoming more
widespread. In 2012, a Lancet editorial commented ‘ . . . surely, the question now is not “why should
pulse oximetry screening be introduced?” but “why should such screening not be introduced more
widely?”’ [17]. The papers within this special edition book for the International Journal of Neonatal
Screening address many of the broader aspects of POS beyond the basic test accuracy; topics include
acceptability, cost-effectiveness, screening in different settings—such as outside the newborn nursery
environment and at altitude—and, importantly, implementation of POS in different countries and
clinical settings and establishing a screening system which suits the local population.
Giving appropriate information and assessing the acceptability of any screening test—both to the
patients involved and to the clinical staff who administer it—is vital if it is to be successful. Previous
studies have shown that POS is acceptable to parents and clinical staff [12,18,19] and also that it does
not appear to create additional anxiety in the mothers (including those who have a false positive
result) [18]. In this special edition, Cloete et al. report feedback from parents on both the information
they received prior to testing and their overall satisfaction of POS during a pilot screening study in New
Zealand [20]. The cultural diversity and the mainly midwifery-led maternity system in this country
make the positive responses received particularly pertinent. As part of their extensive overview of
the implementation process of POS in the USA—the first country to legislate for mandatory POS of
all newborns—Wandler and Martin also report on their systematic and highly effective approach to
addressing the issues raised by such a huge undertaking [21].
As well as being acceptable, a new screening test must also be shown to be cost-effective. A number
of previous studies in different countries have tried to address this issue [9,22–24].
In their review of this work in this special edition, Scott Grosse and colleagues provide a
comprehensive analysis of the available evidence, including a revised estimate of cost (based on
recent improved survival figures from the US following the introduction of POS), estimating that the
cost could be as low as USD 12,000 per life-year gained [25].
Switzerland, Ireland, and Poland were the first countries to recommend routine POS [16,26],
and in 2011, as described above, the USA was the first country to mandate this test [27,28].
Over the past five years, an increasing number of countries, including Canada [29], the Nordic
countries [30], Saudi Arabia, Abu Dhabi, and Sri Lanka [26], have recommended routine screening.
In Europe, significant progress has been made by a multinational group of clinicians working towards
a Europe-wide implementation of PO screening [31] and recently publishing a European consensus
statement, endorsed by leading figures from European Paediatric and Neonatal Societies [32]. In this
special edition, further national recommendations are published from Germany [33] and South and
Central America [34], in addition to a local study from Valencia, Spain [35], which was one of the
precursors to the recent Spanish recommendation [36]. In the UK, almost half of all maternity units are
screening [37] but there is no national recommendation as yet. In Australia, a different approach has
been taken; in this special edition, Martin Kluckow suggests that pulse oximetry should be considered
a ‘routine vital sign’ of general neonatal wellbeing rather than a test for a specific target such as
CCHD [38]. This allows individual hospitals to screen in a manner which suits them and might make
the process simpler and potentially more acceptable; this is an approach which seems to have worked
in Australia, but in response, Gentles et al. argue that a structured national recommendation would
ensure a more equitable service to the whole population [39]. Kluckow’s reply highlights the fact that
national recommendations are often rather slow and cumbersome and that babies may miss out on
screening until the recommendation is sanctioned [40].
Screening pathways (or algorithms) for POS within the published studies are variable [7,13,41,42].
The main differences are i) site of saturation measurement (the use of a single [post-ductal] saturation
measurement or measuring both pre- and post-ductal saturations) and ii) the timing of screening
(before or after 24 h of age).
Screening algorithms which use only a single post-ductal measurement are potentially quicker
and easier, but investigation of the data from these studies and those using both pre- and post-ductal
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saturations show that a small number of babies with CCHD may be missed by using only a single
post-ductal measurement [16,41,42]. With large populations, this number may become significant,
and the benefits of using two measurements may outweigh the potential minor disadvantages [16,40,42].
Most of the recent recommendations advocate dual site measurements, but Riede and colleagues
recommend post-ductal saturation measurement only [33]. An interesting alternative strategy is
proposed by Walsh and Ballweg from Tennessee USA, who advocate post-ductal saturations with
a higher threshold (97%) for the initial screen and then pre- and post-ductal saturations for those who
require a repeat [43].
As with any screening test, it is important to consider the number of false positives (those babies
who have a positive test but do not have CCHD), and the timing of the PO screen affects the number of
false positive screens [13,41]. Later screening (>24 hours) has a lower rate of false positive tests [13,41];
however, between 30% and 80% of false positive babies have a significant respiratory or infective
condition or non-critical CHD [16,25,42,44]. Earlier screening is mandatory in countries (such as
the UK where the majority of babies are discharged within 24 h after birth or in the Netherlands
where many babies are born outside of the hospital environment). In addition, screening after 24 h
of age may result in up to half of babies with CCHD presenting before POS occurs, sometimes
with an acute deterioration [16,42]. These factors must be considered carefully; although a lower
number of false positives is advantageous in a screening test, if the majority of false positives have a
serious non-cardiac condition which requires urgent treatment, this is clearly a significant additional
benefit [19]. In addition, later screening—after 24 hours—may lead to more babies with CCHD
becoming seriously unwell before testing takes place, which defeats the purpose of screening [16,42].
As more countries engage with POS and high-quality outcome data are collected, the nuances of
modifying and refining the screening algorithms can be modelled with greater precision [42].
Screening babies born outside of the nursery e.g., at home, in a midwifery-led birthing centre, or
on the neonatal intensive care unit (NICU), present particular challenges; with homebirth midwifery
staff often leave the mother and baby shortly after birth, which means that POS must take place within
a couple of hours. However, screening babies in this situation has been shown to be both feasible and
acceptable in a small UK study [45] and a much larger Dutch study [46,47]. In this special edition,
Narayen and colleagues present their experience screening such babies in the Netherlands [48] and
Kim et al. report their findings of screening newborns on the NICU at moderate altitude (1700m) [49].
In summary, PO screening is feasible, cost-effective, and acceptable, and it also reduces the
diagnostic gap for CCHD. This special edition of the International Journal of Neonatal Screening focuses
on a number of issues which are entirely relevant to those who might be considering introducing
such screening.
A universal programme of PO screening in newborns will increase the detection of CCHD, and
importantly, it has also been shown to be useful in identifying other potentially life-threatening clinical
conditions (such as respiratory problems and sepsis), which is an important additional advantage. In a
very important report from the USA, Abouk et al. report a 33% reduction in mortality from CCHD in
US states that had introduced POS compared with those where introduction had not yet occurred [50].
When defining the most appropriate screening algorithm, a balance must be struck between
detection of a serious illness and limiting false positive results, and local circumstances may play a role
in this respect. More data from larger populations may help to refine further the screening algorithm.
Finally, it is also important to remember that PO screening is not a perfect test, and babies with CCHD
may still be missed [15,16]. Therefore, PO screening should be used as an addition to existing screening
methods, and health care workers and parents need to be aware of the limitations of the test.
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